A phase I dose-escalation study of BGB-290, a novel PARP1/2 selective inhibitor in patients with advanced solid tumors.

被引：6
|
作者：
Lickliter, Jason D.
Gan, Hui Kong
Meniawy, Tarek
Yang, Jason
Wang, Lai
Luo, Lusong
Lu, Ni
Millward, Michael
机构：
[1] Nucleus Network, Melbourne, Vic, Australia
[2] Austin Hlth, Melbourne, Vic, Australia
[3] Olivia Newton John Canc Res Inst, Melbourne, Vic, Australia
[4] Sir Charles Gairdner Hosp, Perth, WA, Australia
[5] BeiGene Beijing Co Ltd, Beijing, Peoples R China
[6] Sir Charles Gairdner Hosp, Linear Clin Res, Nedlands, WA, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e17049
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17049
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Safety, antitumor activity, and pharmacokinetics (PK) of pamiparib (BGB-290), a PARP1/2 inhibitor, in patients (pts) with advanced solid tumours: Updated phase I dose-escalation/expansion results
    Voskoboynik, M.
    Mileshkin, L.
    Gan, H.
    Millward, M.
    Au-Yeung, G.
    Meniawy, T. M.
    Kichenadasse, G.
    Zhang, K.
    Zhang, M.
    Mu, S.
    Lickliter, J. D.
    ANNALS OF ONCOLOGY, 2019, 30
  • [2] A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.
    Friedlander, Michael
    Meniawy, Tarek
    Markman, Ben
    Mileshkin, Linda R.
    Harnett, Paul
    Millward, Michael
    Lundy, Joanne
    Freimund, Alison E.
    Norris, Christie
    Wu, John
    Paton, Virginia
    Wang, Lai
    Gao, Bo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [3] Preliminary results of pamiparib (BGB-290), a PARP1/2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumors
    Johnson, M.
    Galsky, M.
    Barve, M.
    Goel, S.
    Park, H.
    Du, B.
    Mu, S.
    Ramakrishnan, V.
    Wood, K.
    Wang, V.
    Lakhani, N.
    ANNALS OF ONCOLOGY, 2018, 29 : 138 - 138
  • [4] A phase I dose-escalation and expansion study of JPI-547, a dual inhibitor of PARP/tankyrase in patients with advanced solid tumors.
    Im, Seock-Ah
    Lee, SeungHwan
    Lee, Keun Wook
    Lee, Youngjoo
    Sohn, Joohyuk
    Kim, Jee Hyun
    Im, Young-Hyuck
    Park, Kyong Hwa
    Oh, Do-Youn
    Kim, Min Hwan
    Park, Yeon Hee
    Kim, Tae Min
    Choi, Yoon Ji
    Lee, Chang-Seok
    Park, Jiseon
    Baek, Nam Seok
    Choi, MiKyung
    Kim, John
    Yu, Eunyoung
    Bang, Yung-Jue
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.
    Friedlander, Michael
    Meniawy, Tarek
    Markman, Ben
    Mileshkin, Linda R.
    Harnett, Paul R.
    Millward, Michael
    Lundy, Joanne
    Freimund, Alison E.
    Norris, Christie
    Mu, Song
    Wu, John
    Paton, Virginia E.
    Wang, Lai
    Gao, Bo
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Phase 1 dose-escalation study of the CDK inhibitor dinaciclib in combination with the PARP inhibitor veliparib in patients with advanced solid tumors
    Shapiro, Geoffrey I.
    Do, Khanh T.
    Tolaney, Sara M.
    Hilton, John F.
    Cleary, James M.
    Wolanski, Andrew
    Beardslee, Brian
    Hassinger, Faith
    Bhushan, Ketki
    Cai, Dongpo
    Downey, Elizabeth
    Pruitt-Thompson, Solida
    Barry, Suzanne M.
    Kochupurakkal, Bose
    Geradts, Joseph
    Unitt, Christine
    D'Andrea, Alan D.
    Muzikansky, Alona
    Piekarz, Richard
    Doyle, L. Austin
    Supko, Jeffrey
    CANCER RESEARCH, 2017, 77
  • [7] A phase I dose-escalation study of the novel gamma secretase inhibitor PF-03084014 in patients (pts) with advanced solid tumors.
    Messersmith, W. A.
    LoRusso, P.
    Cleary, J. M.
    Dasari, A.
    Zhang, X.
    Shaik, M. N.
    Courtney, R. D.
    Randolph, S.
    Shapiro, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumors.
    Berlin, Jordan
    Ramanathan, Ramesh K.
    Strickler, John H.
    Subramaniam, Deeps Suresh
    Hurwitz, Herbert
    Kang, Yoon-Koo
    Kim, Tae-You
    Shepherd, Stacie Peacock
    Xiong, Hao
    Hetman, Robert
    Nickner, Caroline
    Dudley, Matthew W.
    Giranda, Vincent L.
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors
    Li, Huiping
    Liu, Rongrui
    Shao, Bin
    Ran, Ran
    Song, Guohong
    Wang, Ke
    Shi, Yehui
    Liu, Jihong
    Hu, Wenjing
    Chen, Fu
    Liu, Xiaoran
    Zhang, Gairong
    Zhao, Chuanhua
    Jia, Ru
    Wang, Quanren
    Rugo, Hope S.
    Zhang, Yifan
    Li, Guangze
    Xu, Jianming
    CHINESE JOURNAL OF CANCER RESEARCH, 2020, 32 (03) : 370 - +
  • [10] A phase I dose-escalation and PK study of continuous oral rucaparib in patients with advanced solid tumors.
    Kristeleit, Rebecca Sophie
    Shapiro, Geoffrey
    LoRusso, Patricia
    Infante, Jeffrey R.
    Flynn, Michael
    Patel, Manish R.
    Tolaney, Sara M.
    Hilton, John Frederick
    Calvert, Alan Hilary
    Giordano, Heidi
    Isaacson, Jeffrey D.
    Borrow, Jennifer
    Allen, Andrew R.
    Jaw-Tsai, Sarah S.
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345